JAK2 inhibitors for myeloproliferative neoplasms: what is next?

@article{Bose2017JAK2IF,
  title={JAK2 inhibitors for myeloproliferative neoplasms: what is next?},
  author={Prithviraj Bose and Srdan Verstovsek},
  journal={Blood},
  year={2017},
  volume={130 2},
  pages={
          115-125
        }
}
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many have been discontinued. Importantly, the activity of these agents is not restricted to patients with JAK2 V617F or exon 12 mutations… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 8 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 156 REFERENCES

A phase-Ib/II study of ruxolitinib plus pomalidomide in myelofibrosis

  • F Stegelmann, M Bangerter, FH Heidel
  • Blood
  • 2015
Highly Influential
14 Excerpts

Similar Papers

Loading similar papers…